Dr. Sabine Hazan

It causes in cows a disease called Yoni's disease, which is very similar to Crohn's disease. And you see these cows, they're wasted and they're having diarrhea. And basically, if you're unfortunate to have, you know, eaten the meat from that cow, then you may end up having that problem. So is a vaccine the answer? Maybe, but I tend to think that we really need to be more precise.

It causes in cows a disease called Yoni's disease, which is very similar to Crohn's disease. And you see these cows, they're wasted and they're having diarrhea. And basically, if you're unfortunate to have, you know, eaten the meat from that cow, then you may end up having that problem. So is a vaccine the answer? Maybe, but I tend to think that we really need to be more precise.

And I think that's what the microbiome is going to help us.

And I think that's what the microbiome is going to help us.

So bifidobacteria is the bacteria. But there is a genetic component to Crohn's disease, right? That's where the biologics are going after. One important thing about that clinical trial.

So bifidobacteria is the bacteria. But there is a genetic component to Crohn's disease, right? That's where the biologics are going after. One important thing about that clinical trial.

Right, exactly.

Right, exactly.

So you could test, you could join a clinical trial. We have a lot of clinical trials where you could join. We have one on Crohn's disease. We can test your kids and we can kind of tell you, look, we're seeing no bifidobacteria. And that could help your kids with that. The second thing you could do is you could do genetic testing, obviously, to see. But here's the thing.

So you could test, you could join a clinical trial. We have a lot of clinical trials where you could join. We have one on Crohn's disease. We can test your kids and we can kind of tell you, look, we're seeing no bifidobacteria. And that could help your kids with that. The second thing you could do is you could do genetic testing, obviously, to see. But here's the thing.

The majority of people with Crohn's disease that we see in our offices do not necessarily transfer to their kids. That's a relief. And I'll tell you that clinical trial that I did, they came to me to enter a trial where they got quadruple therapy, right? What I realized after the fact was that one third responded and that's how it came on that, oh, well, maybe one third has MAP, right?

The majority of people with Crohn's disease that we see in our offices do not necessarily transfer to their kids. That's a relief. And I'll tell you that clinical trial that I did, they came to me to enter a trial where they got quadruple therapy, right? What I realized after the fact was that one third responded and that's how it came on that, oh, well, maybe one third has MAP, right?

Because it's very difficult to isolate mycobacteria per tuberculosis. Right. And then what happened is the other one third went into having biologics and they were fine on biologics. And then one third ended up developing C. diff. And that's how we discovered because they were taking antibiotics. Right. And so they were on quadruple antibiotic for a long time.

Because it's very difficult to isolate mycobacteria per tuberculosis. Right. And then what happened is the other one third went into having biologics and they were fine on biologics. And then one third ended up developing C. diff. And that's how we discovered because they were taking antibiotics. Right. And so they were on quadruple antibiotic for a long time.

So those patients is who we did fecal transplant on. And out of that population, you know, some resolved and some didn't resolve. So then you have to kind of look at why did some resolve? Did I use the right donor? It happened that, you know, one, if I recall, was taking a lot of nutraceuticals that were the equivalent of antibiotics. You know, there's so many nutraceuticals out there.

So those patients is who we did fecal transplant on. And out of that population, you know, some resolved and some didn't resolve. So then you have to kind of look at why did some resolve? Did I use the right donor? It happened that, you know, one, if I recall, was taking a lot of nutraceuticals that were the equivalent of antibiotics. You know, there's so many nutraceuticals out there.

They're killing the gut. And so no matter how much I was giving him a new microbiome of his daughter, he was not resolving the problem. But another one I treated with a brother, and those are the two cases that come up in my mind, did great and resolved Crohn's disease. So that's how you kind of differentiate.

They're killing the gut. And so no matter how much I was giving him a new microbiome of his daughter, he was not resolving the problem. But another one I treated with a brother, and those are the two cases that come up in my mind, did great and resolved Crohn's disease. So that's how you kind of differentiate.

Absolutely true. I mean, there's so much corruption. Look, the company, the scientists and the investors and investors retracted my hypothesis, you know? So when in medicine does an investor of a product get to have any say in what paper gets to stay or gets retracted, right? Never. And when does a PhD scientist... go to the editor and say, we tracked this paper, we found all these problems.

Absolutely true. I mean, there's so much corruption. Look, the company, the scientists and the investors and investors retracted my hypothesis, you know? So when in medicine does an investor of a product get to have any say in what paper gets to stay or gets retracted, right? Never. And when does a PhD scientist... go to the editor and say, we tracked this paper, we found all these problems.